An NCI-designated Comprehensive Cancer Center

Saul Priceman, Ph.D.

Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
Research Focus
  • Cancer immunotherapy
  • T cell biology
  • Immunology
Biography Menu

Research Teams

  • Hematology & Hematopoietic Cell Transplantation
  • T Cell Therapeutics Research Laboratory

Saul Priceman, Ph.D., is an assistant professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer.

Dr. Priceman received his B.S. in microbiology at University of California Santa Barbara, and his Ph.D. in molecular and medical pharmacology at University of California Los Angeles.

Dr. Priceman is a principal investigator on a Prostate Cancer Foundation Young Investigator award, a co-principal investigator on a Prostate Cancer Foundation Challenge Award and a principal investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR T therapy for metastatic breast cancers and working with his team optimizing new CAR T cell therapies for various other solid cancers.

Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

In The News
An Expert's Voice
Saul Priceman | City of Hope

City of Hope scientist receives $9.28M for CAR T trial for metastatic breast cancer

City of Hope News

City of Hope scientist receives $9.28 million for CAR T cell immunotherapy clinical trial for patients with HER2-positive breast cancer that has spread to the brain


First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases